SELLAS Life Sciences Reports Strong Cash Position and Imminent Phase 3 Trial Results

summarizeSummary

SELLAS Life Sciences reported full year 2025 financial results, highlighting a significantly strengthened cash position of $71.8 million as of December 31, 2025, further bolstered by an additional $42.6 million from warrant exercises in Q1 2026. This provides the company with its strongest financial position in history, extending its operational runway beyond 12 months. The filing also provides a critical update on the pivotal Phase 3 REGAL trial for GPS in AML, which is nearing its final analysis with 72 out of 80 required events recorded. Positive Phase 2 data for SLS009 in r/r AML and its expansion into first-line AML treatment, including a new European collaboration, further underscore the company's pipeline progress. These developments collectively reduce near-term financial risk and set the stage for major clinical catalysts.

check_boxKey Events

• Strengthened Financial Position

  The company reported $71.8 million in cash and cash equivalents as of December 31, 2025, with an additional $42.6 million received from warrant exercises in Q1 2026, bringing total cash to $114.4 million and extending its operational runway beyond 12 months.

• Phase 3 REGAL Trial Nearing Final Analysis

  The pivotal Phase 3 REGAL trial for Galinpepimut-S (GPS) in AML has recorded 72 out of the pre-specified 80 events, indicating that topline results are imminent upon reaching the final event and completing data procedures.

• SLS009 Clinical Program Expansion

  Following positive Phase 2 results in relapsed/refractory AML, the company has dosed the first patient in an 80-patient trial for SLS009 in newly diagnosed, first-line AML patients and entered a European collaboration to expand the program.

auto_awesomeAnalysis

SELLAS Life Sciences reported full year 2025 financial results, highlighting a significantly strengthened cash position of $71.8 million as of December 31, 2025, further bolstered by an additional $42.6 million from warrant exercises in Q1 2026. This provides the company with its strongest financial position in history, extending its operational runway beyond 12 months. The filing also provides a critical update on the pivotal Phase 3 REGAL trial for GPS in AML, which is nearing its final analysis with 72 out of 80 required events recorded. Positive Phase 2 data for SLS009 in r/r AML and its expansion into first-line AML treatment, including a new European collaboration, further underscore the company's pipeline progress. These developments collectively reduce near-term financial risk and set the stage for major clinical catalysts.